Literature DB >> 11704978

Treatment of postmenopausal osteoporosis: an evidence-based approach.

C J Rosen1.   

Abstract

I have outlined several therapeutic approaches to the prevention and treatment of PMO. As we enter the 21st century it is certain that even more options will become available for the physician. But, several issues are still unresolved and will require more extensive investigation. These include the following: 1. Employing intermittent (weekly or monthly) oral or intravenous bisphosphonate therapy to treat PMO. 2. Using combination therapy such as an anabolic agent and an anti-resorptive to further reduce fracture risk and enhance BMD. 3. Understanding the various factors which contribute to fracture risk reduction independent of changes in bone mineral density. 4. Defining the role of biochemical markers in predicting fracture risk reduction. 5. Designing new SERMS which combine the best properties of estrogen and estrogen-like products while avoiding significant side effects. What is certain, is that there are now cost effective treatments for this disease. It remains up to the practicing physician to select, based on the existing evidence, treatments most appropriate for the individual patient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704978     DOI: 10.1023/a:1010002907247

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  47 in total

1.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

Review 2.  How many women have osteoporosis now?

Authors:  L J Melton
Journal:  J Bone Miner Res       Date:  1995-02       Impact factor: 6.741

Review 3.  Identifying relevant studies for systematic reviews.

Authors:  K Dickersin; R Scherer; C Lefebvre
Journal:  BMJ       Date:  1994-11-12

Review 4.  Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis.

Authors:  D J Cook; D L Sackett; W O Spitzer
Journal:  J Clin Epidemiol       Date:  1995-01       Impact factor: 6.437

Review 5.  Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis.

Authors:  J W Nieves; L Komar; F Cosman; R Lindsay
Journal:  Am J Clin Nutr       Date:  1998-01       Impact factor: 7.045

6.  Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

Authors:  P D Miller; N B Watts; A A Licata; S T Harris; H K Genant; R D Wasnich; P D Ross; R D Jackson; M S Hoseyni; S L Schoenfeld; D J Valent; C H Chesnut
Journal:  Am J Med       Date:  1997-12       Impact factor: 4.965

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.

Authors:  S M Ott; G C Woodson; W E Huffer; P D Miller; N B Watts
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

9.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors:  S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal:  Am J Med       Date:  1993-12       Impact factor: 4.965

10.  Clinical experience with etidronate in osteoporosis.

Authors:  P J Ryan; I Fogelman
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

View more
  1 in total

1.  Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.

Authors:  N Binkley; H Bone; J P Gilligan; D S Krause
Journal:  Osteoporos Int       Date:  2014-07-16       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.